Non-invasive delivery mechanisms for producing physiological effects in the body

Abstract

A system and method for producing a physiological effect on a living organism in response to a simulated stimulus. The system includes a wearable device for delivering a drug-mimicking signal to a human to produce a desired physiological effect. These wearable devices can be used to induce the physiological effect by applying an electromagnetic or magnetic field to one or more regions of the living organism and to collect data regarding the health of the user. This data can be processed to select one or more cognates and adjust the amount of power applied and the duration of exposure of the drug-mimicking signal delivered to the human.

Description

[Technical field]

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 294,054, filed December 27, 2021, which is incorporated by reference in its entirety. [Background technology]

[0002] Living organisms continually undergo various physiological effects under typical and non-typical conditions. For example, humans can produce certain hormones in response to stress induced by external stimuli that affect the human body's functions. Humans can move from one physiological state to another when their environment or stimuli change. This stimuli may have beneficial physiological effects. For example, humans can take drugs that alleviate the undesirable symptoms of various diseases and poor health conditions, or can undergo physical interactions that bring about such relief. For example, diazepam is a drug that, when taken, can affect the human physiology to reduce anxiety, seizures, etc. This drug can be taken orally, inserted rectally, injected intramuscularly, injected intravenously, or used as a nasal spray. These effects of this drug begin to appear at different times depending on the form in which the drug is taken.

[0003] One reason for the existence of various methods of taking medicines is that the effect of a drug can be determined by how an individual processes the drug. For example, when administered intravenously, the effect of the drug can begin to appear within 1-5 minutes and can last for an hour. When administered orally, the effect can begin to appear between 15-60 minutes after administration. Furthermore, some people may prefer or have a physical aversion to certain forms of intake. However, there is still a desire to avoid taking a drug altogether while still enjoying the same physiological benefits. Furthermore, any drug has side effects, such as suicidal thoughts, respiratory depression, agitation, etc. It is therefore desirable to be able to enjoy all the benefits of the drug while reducing or preventing its side effects. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] U.S. Patent No. 6,724,188 [Patent Document 2] U.S. Patent No. 6,995,558 [Patent Document 3] U.S. Patent No. 6,952,652 [Patent Document 4] U.S. Patent No. 7,081,747 [Patent Document 5] U.S. Patent No. 7,412,340 [Patent Document 6] U.S. Patent No. 7,575,934 [Patent Document 7] U.S. Patent No. 9,417,257 [Patent Document 8] U.S. Patent No. 10,046,172 [Patent Document 9] U.S. Patent No. 11,103,721 [Patent Document 10] PCT / US2009 / 002184 Summary of the Invention

[0005] Many aspects of the present technology may be better understood by reference to the following drawings. The components in the figures are not necessarily drawn to scale. Instead, emphasis is placed on clearly illustrating the principles of the present technology. Thus, various elements may be arbitrarily enlarged to improve readability. For ease of reference, the same reference numbers may be used throughout the disclosure to identify identical or at least substantially similar or approximate components or features. [Brief description of the drawings]

[0006] [Figure 1]FIG. 1 illustrates a system comprising wearables for delivering a drug-mimicking signal to a human or subject to simulate a desired physiological effect. [Figure 2A] FIG. 2 is a schematic diagram of a cable and coil assembly during manufacturing. [Figure 2B] FIG. 2 is a schematic diagram of a cable and coil assembly during manufacturing. [Diagram 3] FIG. 1 shows an example of an implementation of a connector core for a cable and coil assembly. [Figure 4] 1A-1D illustrate a method of manufacturing a coil and cable assembly. [Diagram 5] FIG. 1 illustrates a method for enhancing a drug-simulating signal. [Figure 6] FIG. 1 illustrates a method of operating a system configured to provide non-invasive, non-thermal, and mobile magnetic field therapy. [Figure 7] FIG. 13 shows a Helmholtz configuration with coils that allow for targeting of a drug-simulating signal towards an object located between the coils. [Figure 8] FIG. 1 is a schematic diagram illustrating a non-uniform array of devices with signal generators located in a vehicle. [Figure 9] FIG. 1 is a block diagram illustrating a system with machine learning (ML) capabilities to improve the effectiveness of a drug mimicking signal. [Figure 10] FIG. 1 is a block diagram illustrating an example computer system that may implement at least some of the operations described herein. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] The disclosed technology includes a non-invasive delivery mechanism for producing a physiological effect in a living organism. This technology overcomes the drawbacks of conventional methods for delivering pharmaceuticals or other substances that produce a physiological effect when taken up or otherwise introduced into a target living organism ("body"). The drawbacks of conventional methods include being invasive, and the substance itself may cause undesirable side effects. The disclosed technology includes electromagnetic signals that are emitted to tissues of a living organism to simulate the physiological effect of a recorded compound on the body. These recorded signals are referred to herein as "drug mimicking signals" or "cognates" and are designed to simulate the electrostatic potential of a particular molecule or compound in the body that is generated in response to a recorded physical molecule. That is, the cognates include signals that approximately replicate the magnetic field emanating from one or more predetermined chemical, biochemical, and / or biological molecules.

[0008] More generally, the system may record signals associated with or from chemical, biochemical, or biological molecules. These recordings correspond to the electrostatic potential of the chemical, biochemical, or biological molecules or agents used to produce a physiological effect. In one implementation, a magnetometer may detect a magnetic field. The movement of charges caused by the molecules creates a magnetic field that is detectable by the magnetometer. This magnetic field induces a voltage in a superconducting quantum interference device (SQUID) amplifier that then maintains a constant voltage. This voltage may be recorded.

[0009] In some cases, the substance may provide a counteracting effect on discomfort or other adverse health conditions. In one implementation, the transduction technology is coupled via Bluetooth (or other communication technology) to a device equipped with biosensor technology, such as a smart watch. In one implementation, a standalone biosensor can monitor the sleep patterns of an organism and select and transmit the appropriate signal or cognate via a Bluetooth connection to achieve a desired effect, such as better sleep. In another implementation, the biosensor detects biometric signs of anxiety, such as increased heart rate, pulse, and blood pressure. The sensor can communicate with the transduction device to deliver the appropriate signal or cognate to reduce anxiety.

[0010] The systems and methods disclosed herein may be configured to produce or mimic similar physiological effects produced by the delivery of chemical, biochemical, or biological agents to humans or other subjects without the use of drugs. For example, some techniques may involve generating efficacious fields, including electromagnetic or magnetic fields, that simulate the signals of chemical, biochemical, or biological agents. Thus, the systems and methods of the present technology allow a human to receive an electronic "prescription," i.e., the administration of electromagnetic or radio frequency (RF) energy, such as by clicking a button. Thus, the techniques described herein may be non-invasive, non-thermal, and mobile.

[0011] As used herein, the term "drug" may broadly refer to any chemical, biochemical, or biological molecule, including pharmaceuticals, proteins, RNA and DNA sequences, or any other substance or agent that can cause a physiological effect. Additionally, as used herein and as described in more detail below, terms such as "magnetic field" and "electromagnetic field" are used interchangeably to refer to the targeting of energy to selected regions of an organism to produce a physiological effect that can, for example, produce beneficial effects and address adverse health effects. Additionally, RF energy has properties that simulate the effects of certain drugs.

[0012] In some implementations, these induced physiological effects may relieve pain or alleviate central nervous system (CNS) disorders such as depression, anxiety, post-traumatic stress disorder, and even symptoms of movement disorders. Drug-mimicking signals may provide other physiological effects, such as caffeine or other stimulants or sedatives. Additionally, drug-mimicking signals may be combined to provide desired physiological effects.

[0013] The strength of this signal can be adjusted up or down within a range that produces an effective field; that is, only that narrow range of a signal can produce an effective effect, so that raising the strength above an upper threshold or lowering it below a lower threshold will not cause the body to produce the desired physiological effect. This can be true regardless of the shape and size of the body. For example, the same narrow range of strength is required to produce the desired physiological effect for both a man weighing 200 pounds and a woman weighing 150 pounds.

[0014] FIG. 1 illustrates a system 100 comprising wearable devices (hereafter "wearables") for producing a desired physiological effect by delivering drug-simulating signals to a human. As illustrated, the wearables can operate as a system or individually to selectively induce the effect of a drug, such as an antidepressant. Thus, the wearables can induce the physiological effect of a psychotropic drug by applying electromagnetic or magnetic fields to one or more regions of the living body. These fields are induced or generated to expose specific regions of the body with signals that simulate the drug. Of course, while a human is shown, the technology discussed herein can be used with other living organisms, such as animals, to create a comfortable experience, reduce discomfort, etc. Findings regarding biological signals used to simulate drugs are discussed in more detail in patent applications and patents commonly owned by the assignee of the present application. These patents and patent applications include U.S. Patent No. 6,724,188, U.S. Patent No. 6,995,558, U.S. Patent No. 6,952,652, U.S. Patent No. 7,081,747, U.S. Patent No. 7,412,340, U.S. Patent No. 7,575,934, U.S. Patent No. 9,417,257, U.S. Patent No. 10,046,172, U.S. Patent No. 11,103,721, and PCT application PCT / US2009 / 002184, all of which are incorporated herein by reference in their entirety.

[0015] The wearables may offer various advantages over invasive forms of delivering substances that produce a desired physiological effect. For example, wearables are portable, allowing a person to receive treatment at home, work, school, and during recreation. Furthermore, the wearables may allow for the simulation of the effects of taking drugs without visiting a medical facility, without incurring long recovery times, and potentially without suffering side effects such as nausea, fatigue, loss of appetite, and infection. Furthermore, these signals can be tailored to optimize physiological effects in ways not easily possible with traditional drugs.

[0016] As shown, the wearables can be component parts that act collectively or independently to produce a physiological effect. These component parts include various wearables. These various wearables are smart electronic devices (e.g., microcontrollers, etc.) worn near and / or on the surface of the skin, where they can detect, analyze, and transmit information, such as body signals (e.g., vital signs) and / or ambient data, to provide biofeedback to the wearer. Wearables, such as activity trackers, are an example of Internet of Things (IoT) devices that contain electronics, software, sensors, and / or connectivity capabilities that allow objects to exchange data over the Internet with manufacturers, operators, and / or other connected devices without the need for human intervention.

[0017] Wearables can be used to collect data on the user's health, such as heart rate, calories burned, steps taken, blood pressure, release of certain biochemicals, exercise time, seizures, physical strain, etc. Data collected by wearables can be used to, for example, predict changes in mood, stress, and health status, measure blood alcohol concentration, measure athletic performance, monitor the degree of illness of the user, perform long-term monitoring of humans with cardiac and circulatory disorders, and perform health risk assessments. This data can be processed to select one or more cognates and adjust the amount of power applied and the duration of exposure of the drug-mimicking signal delivered to the human. Additionally, wearables can instantly deliver signals and dynamically change the "dose" emitted to the body (e.g., adjust the duration of exposure to the drug-mimicking signal).

[0018] In the illustrated example, the wearables include a smart watch 102, smart glasses 104, and a wearables display device 106 on the forearm. The smart watch 102 may provide a local touchscreen interface for everyday use, and an associated mobile application on a smartphone (not shown) provides management and telemetry (e.g., biometric monitoring). The smart watch 102 may include applications, a mobile operating system, and Wi-Fi / Bluetooth connectivity capabilities. The smart glasses 104 add information in parallel to what the wearer sees. Alternatively, the smart glasses 104 may change optical properties at run time. Overlaying information over the field of view is achieved by optical head-mounted display (HMD) glasses or embedded wireless glasses with transparent heads-up display (HUD) or augmented reality (AR) overlays. Modern smart glasses are essentially wearable computers capable of running standalone mobile applications. Some of them are hands-free and can communicate with the Internet via natural language voice commands, while others use touch buttons.

[0019] In one example, the smart glasses 104 are part of a headgear that may be used to position a signal generator (e.g., a coil) around a human's skull. The headgear may include breathable mesh, elastic straps, and bands that may provide a comfortable device for holding, securing, or positioning the coil around a human's skull. Additionally, the headgear may include fasteners for securing the bands over the coil. These fasteners may work with Velcro, snaps, or other types of fastening devices.

[0020] The wearables display device 106 can function similarly to a smartphone, combining mobile phone and computing capabilities in one unit. What distinguishes the wearables display device 106 from other smart devices is that it has more powerful hardware capabilities and a broader mobile operating system, allowing it to leverage a wider range of software, Internet, and multimedia capabilities in addition to its core functions. The wearables can include multiple integrated circuit (IC) chips with various sensors, such as magnetometers, proximity sensors, barometers, gyroscopes, and accelerometers, and can support wireless communication protocols, such as Bluetooth, Wi-Fi, or satellite navigation.

[0021] According to some implementations, the wearables or other devices may be secured to the human by using fasteners such as tape, elastic bandages, or gauze. A system including the wearables may include a controller and a battery charging device. For various security reasons, each component may be manufactured such that the housing cannot be easily opened. To allow the human to continue to experience the effect of the cognate, one or more additional components may be provided, allowing the human to enjoy the effect even if any of the wearables are inoperable. In one example, these components of the system are disposable, or the entire system including one or more of these components is disposable.

[0022] In one implementation, each component includes a signal generator for generating an effective field, including an electromagnetic signal directed toward the location of the human where the particular component is worn. In one example, the signal generator includes a coil and / or transmitter having one or more conductors configured to generate a magnetic or electromagnetic field to generate a drug-mimicking signal that simulates the physiological effect of the drug on the living body. The signal generator can be configured to have various electromagnetic properties. Furthermore, the signal generator may be surrounded by a plastic or other composite material to both protect the windings of the coil (e.g., the signal generator) and provide a comfortable contact surface for the wearer. The signal generator can be flexible and malleable, can have various shapes, can have various sizes or types, and can even include a rigid coil. Advantageously, these signal generators can transmit the drug-mimicking signal by being fixed externally to the human body as opposed to being inserted subcutaneously within the human body.

[0023] The signal generator can have various shapes and / or sizes. For example, the signal generator can include a small circular encapsulation coil, a large circular encapsulation coil, a rectangular encapsulation coil, and / or a substantially square encapsulation coil. Each shape may provide advantages for acting on a particular part of the human body. Signal generators of various dimensions can be manufactured to more effectively apply the drug-simulating signal to areas of various sizes. Each signal generator can have an inner and / or outer diameter or length ranging from just a few centimeters to several feet depending on various implementations.

[0024] In one implementation, the wearable has a cable connecting the coil to a controller for sending various signals to the coil. The cable may include two or more conductors and strength members. Each of these conductors and members may perform a specific function. For example, some conductors may be electrically connected to each end of the coil to allow current to flow to and from the coil, thereby actuating, triggering, inducing, or otherwise exciting the coil. A shield conductor may be coupled to ground and configured to provide electromagnetic shielding for the conductor. The strength members may be secured to the coil and connector to provide strain relief for the conductor. In some implementations, the strength members are manufactured with a shorter length than the other conductors so that the strength members bear the majority of the tension applied between the coil and the connector.

[0025] The system and / or its component parts may communicate using encryption to, for example, thwart hacking. That is, the system may implement multiple types of encryption protocols to protect the signal data. In one example, the system uses asymmetric encryption employing a key pair, i.e., a private key and a public key. Symmetric encryption, which uses the same key for encryption and decryption, may also be used, but may be less secure. Additionally, hashing may be used to verify the integrity of the signal data. Hashing generates a fixed length value associated with the file comprising the signal recording.

[0026] The files processed by the wearables to generate drug-simulating signals, or the signals themselves, may contain metadata to aid in pre- or post-processing. For example, the files or signals may contain an indication of the signal source, expected physiological effect, or other variables, such as information regarding sample preparation, concentration, and / or solvent data, in the header information of each record. Other metadata that may be included in the header include a serial number for tracking and variables that have been fine-tuned for signal optimization.

[0027] The wearable may incorporate a signal generator (e.g., a coil) that is coupled to a controller via a cable. Any or some of these components may be internal or external to the wearable. For example, FIGS. 2A and 2B show schematics of a cable and coil assembly during manufacturing. A cable 204 connects the coil 202 to a connector 206, which allows a controller (not shown) to send various signals to the coil 202 via the cable 204. The cable 204 includes conductors 208a, 208b, a shield 208c, and a strength member 208d (collectively referred to as "conductors 208"). Each conductor 208 is configured to perform a specific function. For example, the conductors 208 may be electrically connected to each end of the coil 202 to allow current to flow to and from the coil 202, thereby actuating, triggering, inducing, or otherwise exciting the coil 202. Shield conductor 208c can be coupled to ground and configured to provide electromagnetic shielding for conductors 208a and 208b. Strength member 208d can be secured to coil 202 and connector 206 to provide strain relief for conductors 208a-208c. In some implementations, strength member 208d is fabricated with a shorter length than the other conductors so that the strength member bears a majority of the tension applied between coil 202 and connector 206.

[0028] As shown in FIG. 2B, the connector 206 has three parts: (1) a connector core 207, (2) a connector housing 210a, and (3) a second connector housing 210b. The connector housings 210a and 210b encapsulate the connector core 206 to protect the traces and electronic devices carried by the connector core 207. FIG. 3 illustrates one implementation of the connector core 207. The connector core 206 has a controller end 302 and a cable end 304. The controller end 302 is configured to matingly couple to a controller, and the cable end 304 is configured to provide an interface for the conductors 208. In some implementations, the strength members 208d are secured against one or more holes 306 to provide strain relief. Additionally, the conductor core 207 may have traces 308 to which the conductors 208 are electrically coupled to facilitate communication with the controller.

[0029] As a security feature of the coil and cable assembly, the connector core 207 may include an integrated circuit 310. The integrated circuit 310 may be a microprocessor or may be a stand-alone memory device. The integrated circuit 310 may be configured to communicate with the controller via the controller end 302 using communication protocols such as I2C and 1-Wire. The integrated circuit 310 may include a digital ID of the coil associated with the connector core 306. The digital ID stored in the integrated circuit 310 may allow for ascertaining electrical characteristics of the coil, such as impedance, inductance, and capacitance. Additionally, the integrated circuit 310 may be configured to store and provide additional information, such as the length of the coil's conductor, the physical dimensions of the coil, and the number of turns of the coil.

[0030] In some implementations, the integrated circuit 310 includes information, such as a unique identifier, encrypted data, or encrypted information, to prevent reuse in a stolen or counterfeit system. For example, the information in the integrated circuit 310 may include an encrypted identifier representing a measurable characteristic of the coil and / or an identifier for the integrated circuit. If the encrypted identifier is simply copied and stored in another integrated circuit, such as by an unauthorized manufacturer of the coil and cable assembly, the controller may recognize that the encrypted identifier is not authentic and block signal transmission. In some implementations, the integrated circuit stores one or more encryption keys, digital signatures, shorthand data, or other information to enable communications and / or security features associated with public key infrastructure, digital copy protection schemes, or the like.

[0031] FIG. 4 illustrates a method 400 for manufacturing a coil and cable assembly, such as the coil and cable assemblies described above, for use in providing a non-invasive, non-thermal, and ambulatory system.

[0032] At block 402, the electrical coil is encapsulated within a flexible composite material that allows the electrical coil to be comfortably fixed to the patient's body for providing magnetic field therapy (e.g., drug-mimicking signals, etc.).

[0033] At block 404, the electrical coil is coupled to the connector via a cable to facilitate reliable transfer between the connector and the electrical coil. The cable may include multiple conductors that deliver signals between the connector and the electrical coil and may provide mechanical strain relief for the signal carrying conductors.

[0034] In block 406, an integrated circuit is coupled to a connector, cable, or electrical coil. The integrated circuit may be coupled to a connector, for example, via one or more electrical conductors that may or may not be coupled to an electrical coil. In block 406, other components, such as smart eyewear components, may be added, incorporated, or coupled to the coil, connector, and integrated circuit.

[0035] At block 408, information is stored in the integrated circuit to identify or uniquely identify the individual or combination electrical characteristics of the integrated circuit, connector, cable, and / or electrical coil. This information may be a hash or other cryptographic unique identifier based on information that may be unique to other portions of the integrated circuit and / or coil and cable assembly. This security feature may be used to prevent or inhibit unauthorized remanufacturing of coil and cable assemblies compatible with the controller of this treatment system. Additional security features are described herein (e.g., in connection with operation of the controller of the treatment system).

[0036] The coil and cable assembly may be encapsulated within the wearable such that the wearable operates as a closed system for delivering the drug-mimicking signal to the living body. The delivery of the drug-mimicking signal by the closed system is controlled by a program stored in the memory of the wearable. The program is further operable to respond to feedback collected by the wearable. In some implementations, the closed system includes an amplifier circuit. The closed system generates feedback by allowing at least a portion of the amplifier circuit's output signal to return to its input. Such implementations may improve control of the output. For example, if an actual output of the amplifier circuit is compared to a desired output, the comparison may be utilized to fine-tune the output to achieve the desired output.

[0037] In other implementations, the amplifier circuitry can be programmed to adjust the strength and / or amplitude of the drug-mimicking signal sent to the organism. In such implementations, the signal can be maintained within a certain range or adjusted to achieve a desired physiological effect in the organism. Furthermore, feedback allows the closed system to dynamically adapt to any requirements necessary to achieve the desired physiological effect.

[0038] Alternatively, a handheld device (e.g., a smartphone) can be wirelessly coupled to the wearable and control a signal generator within the wearable to deliver the drug-mimicking signal. In this case, the signal generator assembly integrated into the wearable can be wirelessly coupled to other devices as part of a system that produces a physiological effect based on the drug-mimicking signal.

[0039] System Controller The controller can provide an interface to the human to distribute and condition the drug-simulating signal to the signal generator and prevent unauthorized copying and / or distribution of the drug-simulating signal. According to various implementations, the controller can include various features, such as a housing, a processor, memory, a visual interface, and an audio interface, as well as other features not shown or described herein for brevity. In one implementation, a microcontroller circuit is configured to operate the controller. The circuit can include a microprocessor, a reset circuit, and a volatile memory. The microcontroller can be a standard microprocessor, microcontroller, or other similar processor, or alternatively a tamper-resistant processor for improved security. The microprocessor can include multiple analog and / or digital communication pins to support communication with electronics located both outside and inside the housing. The microprocessor can include (1) a USB connector to support communication via a USB protocol, (2) a display connector to communicate with the visual interface, and (3) an audio connector to provide an audio interface, as well as other data communication pins.

[0040] The microcontroller can securely receive prescription files from one or more external devices via a connector or wirelessly. Encrypting the prescription file increases the security of the prescription file contents. Cryptographic systems regularly suffer from a problem known as the key distribution problem. The standard assumption in the cryptography community is that an attacker will know (or can easily discover) the encryption and decryption algorithms. All that is needed to decrypt an encrypted file and reveal its private contents is the key. A legitimate user of the information must have this key. Distributing the key in a secure manner mitigates the key distribution problem.

[0041] In some embodiments, the microcontroller is configured to use the Advanced Encryption Standard (AES). AES is a specification for encryption of electronic data established by the National Institute of Standards and Technology (NIST) and is used for financial transactions between institutions. It is a symmetric encryption standard (the same key is used for encryption and decryption) and can be secure while maintaining key distribution security. In some implementations, the microcontroller uses a 128-bit AES key that is unique to each controller and stored in non-volatile memory. The encryption key can be random to reduce the possibility of counterfeiting, hacking, or reverse engineering. The encryption key can be loaded into the non-volatile memory during the manufacturing process or before the controller is shipped to the customer (physician or patient). Utilizing AES encryption allows prescription files to be encrypted and uploaded to one or more servers to facilitate selective delivery to various controllers.

[0042] For example, a doctor or other medical professional may obtain approval to download a prescription file for a patient to the controller. When the doctor contacts and logs into the server to obtain the prescription file, the doctor may first need to provide certain information. For example, the doctor may need to identify the target device (controller) to the server (e.g., by a globally unique ID (GUID) stored in the controller) so that the server can search for the target device in a database and provide a prescription file encrypted with a key compatible with the controller. The encrypted prescription file may then be loaded into the non-volatile memory via the microcontroller using USB or another communication protocol. Alternatively or additionally, the encrypted prescription file may be stored directly to the non-volatile memory during the manufacturing process and before the front and rear portions of the housing are sealed together to reduce the possibility of the prescription file being intercepted.

[0043] The microcontroller may also be configured to log the patient's use of the therapeutic system. The log may be stored in non-volatile memory and downloaded by the medical professional when the patient returns the controller to the prescribing medical professional, such as after the controller's allotted time has been reached. The log may be stored in a variety of data formats or files, such as delimited values, text files, or spreadsheets, so that the medical professional may view an activity report of the controller. In some implementations, the microcontroller may be configured to log information regarding errors associated with the coil connection, electrical characteristics of the coil over time, date and time of use of the therapeutic system, battery charge duration and discharge trajectories, and inductance measurements or other readings of the coil placed in contact with the patient's body. The microcontroller may provide the log data or log file to the medical professional using a USB port or other communication mode, allowing the medical professional to evaluate the quality and / or functionality of the therapeutic system and the amount and / or use of the therapeutic system by the patient. Among other things, the microcontroller can be configured to log any interruptions in signal delivery and can log errors, status messages, or other information that is provided to a user via the controller's user interface (e.g., an LCD screen, etc.).

[0044] The microcontroller can be configured to protect the contents of the prescription file using volatile memory. In some implementations, the prescription file is encrypted when the microcontroller transfers the prescription file from an external source to the non-volatile memory. Additionally, the microcontroller can be configured to store only a decrypted version of the contents of the prescription file in the volatile memory. By limiting the storage of the decrypted content to volatile memory, the microcontroller, and therefore the controller, can ensure that the decrypted content is lost when power is removed from the microcontroller circuitry.

[0045] The microcontroller may be configured to implement additional security measures to reduce the likelihood of unauthorized users obtaining the contents of the prescription file. For example, the microcontroller may be configured to decrypt the prescription file only after verifying that an authorized or authentic coil and cable assembly is connected to the controller. As previously described, the coil and cable assembly may include an integrated circuit that may store one or more encrypted or unencrypted identifiers of the coil and cable assembly. In some implementations, the microcontroller is configured to verify that an authorized or authentic coil and cable assembly is connected to the controller. The microcontroller may verify that the coil and cable assembly is authentic by comparing the identifier from the integrated circuit of the coil and cable assembly to one or more entries stored in a lookup table in either a volatile or non-volatile memory. In other implementations, the microcontroller is configured to obtain a serial number of the integrated circuit, measure electrical characteristics of the coil and cable assembly, and perform a cryptographic function, such as a hash function, on the combination of the serial number and the electrical characteristics. Doing so may deter or prevent unauthorized users from copying the contents of the integrated circuit of the coil and cable assembly into a duplicate integrated circuit associated with an unauthorized copy of the coil and cable assembly.

[0046] The microcontroller can be configured to delete the prescription file from the volatile and non-volatile memory in response to one or more predetermined conditions being met. For example, the microcontroller can be configured to delete the prescription file from memory after the controller delivers a prescription drug simulating signal for a particular period of time, such as 14 days. In other examples, the microcontroller is configured to delete the prescription file from memory after the controller detects that a device housing the coil and cable assembly has been hacked. The microcontroller can be configured to delete the prescription file after only one connection with an unauthorized coil and cable assembly, or after a predetermined number of connections with unauthorized coil and cable assemblies. In some implementations, the microcontroller is configured to monitor an internal timer and delete the prescription file, for example, one month, two months, or more after the prescription file is installed on the controller.

[0047] The microcontroller can delete the prescription file from the volatile and non-volatile memory in response to input from one or more sensors (e.g., of the wearable). The sensor can send a signal to the microcontroller in response to a physical disruption of the housing of the controller. For example, the sensor can be a light sensor that detects visible and non-visible wavelengths in the electromagnetic spectrum. For example, the sensor can be configured to detect infrared, visible, and / or ultraviolet light. The microcontroller can be configured to delete and / or destroy the prescription file upon receiving a signal from the sensor, since light detected within the housing can be indicative of an intrusion into the housing. In some implementations, the sensor is a light sensor. In other implementations, the sensor is a pressure sensor, a capacitance sensor, a humidity sensor, a temperature sensor, or the like.

[0048] In response to detection of tampering with the controller or to improve the user friendliness of the therapy system, the microcontroller may use various indicators or interfaces to provide information to the user. One example may include a graphic icon and an audible sound on a display device. The microcontroller may display a graphic icon and activate an audible sound in response to a user error, tampering, or to provide a friendly reminder about deviations from a scheduled use of the therapy system. Additionally, multiple visual indicators (such as LEDs) of various types or colors may be utilized. Additionally, the sound generator may be a vibration motor or a speaker that delivers audible commands to facilitate use of the system by the visually impaired.

[0049] The microcontroller can operate an interface for interacting with a user. The interface can receive various commands from the microcontroller. In response to inputs received from the microcontroller, the screen can be configured to display various messages to the user. In some implementations, the screen displays messages regarding battery status, prescription drug use duration, information regarding the type of prescription drug being administered, error messages, or coil and cable assembly identification. For example, the screen can present the percentage or duration of remaining battery power. Additionally, the screen can provide a text-based message to inform the user that the battery charge is low or that the battery is nearly discharged. Additionally, the screen can be reconfigured to present the name of the prescription drug (e.g., the name of the corresponding physical drug) and / or the body part where the prescription drug is used. Additionally, the screen can present a notification of the elapsed or remaining time for administration of the prescription drug. If additional prescription drug time is not authorized, the screen can inform the user to contact a medical professional.

[0050] The screen can be configured to continuously or periodically provide an indication of the connection status between the coil and the controller. In some implementations, the screen can be configured to display a status or instruction such as "Coil Connected", "Coil Not Connected", "Coil Identified", "Coil Unrecognized", or "Coil Reconnect". In some implementations, the screen can provide a graphical representation of the coil and flash the coil when it is properly or improperly connected. Alternatively or additionally, the controller can monitor the impedance from the coil to detect a change in the coil, a possible removal of the coil, or a loss of the coil from the treatment area and provide a corresponding error message. In other implementations, the interface is a touch-sensitive screen that provides information to the user in addition to receiving instructions or commands from the user. In some implementations, the microcontroller can be configured to receive input from hardware buttons and switches, such as to turn the controller on or off. The switches on the device provide on / off capability of the therapy, allowing the patient to selectively turn their therapy on or off as needed.

[0051] A signal generation circuit may be used to drive the coil and cable assembly with a drug-simulating signal. This circuit may include an audio coder-decoder, an output amplifier, and a current monitor. The audio coder-decoder may be used to convert a digital input received from a volatile memory, a non-volatile memory, or a microcontroller into an analog output signal useful for driving the coil and cable assembly. The audio coder-decoder may be configured to output the analog output signal to the output amplifier. In some implementations, the output amplifier is programmable so that the strength or amplitude of the signal sent to the coil may be altered depending on the treatment prescribed for the person.

[0052] Because the controller can interface with coils having various sizes, shapes, and numbers of turns, the output amplifier can be configured to adjust the intensity level of the signal delivered to the coils so that each coil delivers a uniform drug-mimicking signal between different coils for a particular prescription. The dimensions and electrical properties of the coils can determine the depth and width of the magnetic field focus, and therefore, by programmatically adjusting the output intensity of the output amplifier to deliver a uniform drug-mimicking signal, medical professionals can advantageously select the appropriate coil for a particular patient's body or treatment area without worrying about accidentally changing the prescription. As mentioned above, the controller can determine the dimensions and electrical properties of the coils by reading such information from the integrated circuit. The signal generating circuit can be configured to programmatically adjust the intensity level of the signal output by the output amplifier using the dimension and electrical property information obtained from the coils.

[0053] The output amplifier may include a low pass filter that significantly reduces or eliminates output signals having frequencies above a threshold range, such as 50 kHz. In other implementations, the low pass filter may be configured to significantly reduce or eliminate output signals having frequencies above a threshold range, such as 0-25 kHz. The signal generation circuit may use a current monitor to determine electrical characteristics of the coil and cable assembly and / or verify that the output signal level remains within a specified threshold range. The signal generation circuit may further include a connector that mates with the connector of the coil and cable assembly. The connector may provide an electrical connection between the microcontroller and the coil and cable assembly.

[0054] In one implementation, the system provides an interface to allow a user or operator to select the desired files, the duration of the files, whether the files can be mixed or concatenated to provide a "playlist" for playback, etc. Thus, the interface allows for the selection of different cognates, either individually or as a group, in addition to the duration of the play. In some embodiments, the interface provides a fixed application for a particular cognate or set of cognates that are intended to be emitted continuously. The output power is fixed and not adjustable by the end user to avoid unintended physiological effects.

[0055] Enhancement of drug-mimicking signals Embodiments of the present disclosure include techniques for improving the effectiveness of drug mimicking signals and / or finding the most effective signals. That is, signals simulating a particular drug may be in a very noisy environment. In this case, it may be beneficial to detect the signals despite the presence of noise and to identify among these signals the most effective signal to produce a physiological effect in humans.

[0056] In one implementation, a signal may be emphasized by 1 dB, 2 dB, or more of power across the spectrum between 0 and 6 kHz, then dropped to the noise floor. In this implementation, the nonlinear structure of the signal of interest resides within that bandwidth. Therefore, it may be desirable to remove competing or interfering signals, for example below 6 kHz.

[0057] 5 shows a method 500 for enhancing a drug-simulating signal. The system can perform filtering and / or truncation to enhance only a specific portion of the original signal, which provides a desired physiological effect.

[0058] At 502, the signal is passed through a 6 kHz and / or 7 kHz filter, which greatly improves the effectiveness of the signal. At 504, the signal is downsampled from approximately 44.1 kHz to below 11 kHz, and then at 506, the result is upsampled up to 44.1 kHz. By doing this, content in the signal that is above the noise threshold of the sampling frequency is removed. Furthermore, this results in a sharp roll-off at 79 decibels, and the resulting signal has higher effectiveness. This enhanced signal may therefore increase the onset and perception of the resulting physiological effects.

[0059] In one example, the sampling rates include 11,025 samples per second (s / s), 16,384 s / s, 22,050 s / s, or 44,100 s / s. The signals can be "truncated," meaning that the signals are downsampled from a higher sampling rate to a lower sampling rate, from 44,100 samples / s to 22,050 samples / s, and even down to 11,025 samples / s. Additionally, some embodiments can include low-pass filtering the various signals at 5 kHz and 6 kHz using analog or digital filters, including 4-pole to 8-pole Butterworth filters.

[0060] The file size per signal is reduced by using this low pass filter and down sampling, provided that the remaining files still provide the necessary information. In this case, the low pass filter and down sampling can remove unwanted radio frequency (RF) energy transmitted into the biological system. It is possible that the unwanted RF energy at higher frequencies can compete with the frequencies involved in the physiological effect of interest. In one example, this unwanted RF energy may be referred to as "noise" and may induce electromagnetic interference, which may result in impaired performance of the physiological effect of interest. Additionally, the amplified noise above the target frequency may reduce the signal-to-noise ratio of the target frequency.

[0061] A secondary benefit of the low sampling rate is a significant reduction in file size. In one example, a static offset is used to reduce noise. Some embodiments utilize wideband Fourier analysis to boost power below about 6 kHz, which is responsible for boosting power and biological activity. In some implementations, the system must downsample the signal and resample the signal to a rate of 44,100 Hz. For example, some implementations cannot encode and / or decode signals having a sampling rate less than 44,100 Hz. Other embodiments include signals that can be encoded to allow for multiple sample rates and bit rates.

[0062] In other implementations, and as described above, the signal generating circuit can further include an inductance detection circuit. The inductance detection circuit can be configured to detect a change in the inductance of the coil, which changes as the coil approaches the patient's body. By monitoring the inductance of the coil, the signal generating circuit and the controller can track and record (i.e., log) the patient's use of the treatment system. For example, if a medical professional prescribes 10 hours of treatment system use, but only 3 hours of treatment system 100 use is logged by the controller, the medical professional can better assess the patient's improved, unimproved, or worsening condition. In some implementations, the inductance detection circuit is implemented as a source-follower circuit.

[0063] The controller may include a power control circuit for receiving and regulating power to the controller. The power control circuit includes a power input circuit and a power conditioning circuit. The power input circuit may include a connector (e.g., a micro USB connector) for receiving power from an external source to recharge the battery. The power input circuit may further include a charging circuit that monitors the voltage level of the battery and electrically decouples the battery from the connector when the battery is sufficiently charged. The power conditioning circuit may be used to convert the voltage level of the battery to a low voltage for use by various circuits of the controller. For example, when fully charged, the battery may have a voltage between about 4.2-5 volts, while the microcontroller may have an upper voltage threshold of 3.5 volts. The power conditioning circuit may be configured to convert the high voltage of the battery (e.g., 4.2 volts) to a low voltage (e.g., 3.3 volts) that can be used by the electronic device of the controller.

[0064] FIG. 6 illustrates a method 600 of operating a system configured to provide non-invasive, non-thermal, and mobile magnetic field therapy.

[0065] At 602, an electromagnetic transducer is activated by a controller. The electromagnetic transducer may include coils having various shapes and sizes that are selected depending on the size of the discomfort or condition to be treated.

[0066] At 604, the electromagnetic transducer is secured to an area of ​​the human to be treated. The transducer may be secured by a secured wearable or by the use of an elastic bandage, gauze, tape, or the like.

[0067] At 606, the controller checks for proper connection to the electromagnetic transducer. The controller may be configured to ensure that the proper transducer is coupled to the generator by verifying the identity or electrical characteristics of the electromagnetic transducer, such as the resistance or impedance of the transducer. In some implementations, the controller is configured to periodically monitor the electrical characteristics of the electromagnetic transducer to ensure that the proper connection is maintained. For example, the signal generator may be configured to stop signal delivery to the electromagnetic transducer if the signal generator detects an increase in resistance or a decrease in inductance. The signal generator may stop signal delivery if an unexpected electrical characteristic is detected to protect the health and safety of the patient and prevent unauthorized attempts to obtain the generated signal. As described above, the signal generator may be configured to log periodic checks of the electrical characteristics of the electromagnetic transducer and provide the log data to a medical professional for review. Other security checks may be performed as described herein. In one implementation, a serial number or PIN is required as a two-factor or three-factor authentication security check. The connected smart device may also have scheduling software that can prompt the user to press call or decline a signal. Programs associated with the delivery system may also require the physician or healthcare professional to provide an access code to the patient or user.

[0068] At 608, the controller decodes the signal stored by the controller in response to determining that a proper connection exists between the electromagnetic transducer and the signal generator.

[0069] At 610, an electromagnetic transducer generates a magnetic signal that is directed toward an area of ​​the human. The magnetic signal corresponds to a therapeutic signal stored in a signal generator. According to various embodiments, the magnetic signal has a frequency in the range of 0-22 kHz.

[0070] In some embodiments, a signal from a drug, biologic, or other molecular (chemical, biochemical, biological) sample may be obtained by placing the sample in an electromagnetic shielding structure and in proximity to at least one SQUID coupled to a magnetometer. The drug sample is placed in a container having both magnetic and electromagnetic shielding, where the drug sample serves as a source of molecular signals. In the absence of another signal, noise may be injected into the drug sample at a noise amplitude sufficient to generate stochastic resonance from another signal source, where the noise has a substantially uniform amplitude across multiple frequencies. Using the SQUID or magnetometer, output radiation from the drug sample is detected and recorded as an electromagnetic time domain signal comprised of the drug sample source radiation superimposed on the noise injected in the absence of the other generated signal. The noise injection and radiation detection may be repeated at each of multiple noise levels within a selected noise level range until the drug sample source radiation is distinguishable from the injected noise. In some embodiments, the SQUID has a thermal baffle that is used to slow the boil-off of the cryogenic helium. In some applications, the SQUID further provides an additional electromagnetic shielding layer by adding an additional 3-6 dB of electromagnetic isolation.

[0071] Helmholtz configuration for delivering drug-mimicking signals The drug-mimicking signal may be delivered to the human via a system having a Helmholtz configuration with multiple signal generators (e.g., coils) configured to additionally generate signals targeted to regions between the coils. The array of signal generators is coordinated by a controller to generate and / or transmit signals that can collectively generate sufficient signal energy to cause a physiological effect in the human. The additional and targeted effect of using a Helmholtz configuration may include placing signal generators at various locations that are not in physical contact with the human. Furthermore, the drug-mimicking signal received by the human may result from a combination of lower strength signals, allowing the signal strength of any one signal generator to be relatively low even when physically located far from the human of interest.

[0072] Figure 7 shows a Helmholtz configuration of a signal generator that can target a drug-simulating signal. As shown, the Helmholtz configuration 700 has two identical electromagnetic coils 702-a and 702-b or two solenoids oriented in parallel, positioned one radial distance apart so that both coils operate in phase with each other. This design achieves high magnetic field homogeneity throughout the internal volume of the space between the coils in which a person 704 is positioned. The Helmholtz configuration has the advantage of providing magnetic field homogeneity over a large area compared to a single coil, where the magnetic field falls off rapidly inversely proportional to the square of the distance.

[0073] The Helmholtz configuration can produce an even larger volume of uniformity by adding an additional coil in the center of the Helmholtz array. The addition of multiple center coils can be applied to further increase the volume or extend the physical length of uniformity (e.g., Maxwell coils). In one implementation, the Helmholtz array can be used to apply an ultra-low radio frequency energy (ulRFE) field by placing a coil on each side of a cubicle or in multiple parts of a room where people congregate. Smaller arrays can be repeatedly positioned throughout a room or area where people move around, lengthening the time that a single cognate or experience is experienced as people move around. For example, a Helmholtz array can be used with ulRFE cognates to produce a change in mental state in customers in a department store by inducing feelings of relaxation, happiness, or other feelings that motivate them to stay and shop. Helmholtz arrays can also be used to defuse crowds or to create emotions that may encourage people to leave an area.

[0074] Additionally, a motion detector 706 (e.g., a camera) can be used to track the position of the person 704, allowing multiple signal generators to dynamically adapt based on the position of the person 704, thereby allowing the signal strength of each individual signal generator to be kept relatively low, eliminating the need to fill the entire space with a constant signal.

[0075] FIG. 8 is a schematic diagram 800 illustrating an array of devices comprising signal generators disposed in a vehicle 802. Signal generators 804-a, 804-b, and 804-c (collectively referred to as "signal generators 804") are not physically worn by a driver 806, but still deliver a drug-simulating signal to the driver 806. As shown, the signal generators 804 are positioned at three locations on the vehicle 802 driven by the driver 806. These locations include the windshield, the rear window, and the passenger side window. The coils can be designed to rotate and move to allow for precise positioning and induce a drug-simulating signal. For example, the signal generators 804, as components of one or more arrays, can induce a drug-simulating signal to a human, such as the driver 806 or a passenger. Thus, some embodiments can deliver a drug-simulating signal that can keep the driver 806 alert by producing the physiological effects of caffeine. While shown in the vehicle. In other embodiments, the device array can be positioned in other structures. For example, coils in a Helmholtz configuration can be incorporated into a structure such as a chair. A chair fitted with a Helmholtz coil can provide treatment for CNS disorders. These structures or similar structures may have utility beyond treating CNS disorders. For example, a chair or recliner may be equipped with a Helmholtz array for general wellness and recreational purposes.

[0076] Machine learning features 9 is a block diagram illustrating a system with machine learning (ML) capabilities to improve the effectiveness of a drug-simulating signal. As shown, the system 900 includes a simulator 902 configured to process recordings of electrostatic potentials of chemical, biochemical, or biological molecules associated with physiological effects caused by drugs or other substances.

[0077] The system 900 may include a combination of sensors and / or signal generators 904-a, 904-b, and 904-c disposed on or near a human 906. The sensors and / or signal generators 904-a-904-c generate drug-mimicking signals and / or measure physical characteristics of the human 906, including, for example, temperature and other measurements indicative of the physiological effects of the drug or drug-mimicking signals. For example, the sensor data may be used to determine a numerical value indicative of a particular physiological condition of the human 906.

[0078] These drug-simulating signals and sensor data are communicated via a communication channel between the human 906 and the simulator 902. The sensor data may be periodically generated by the sensors 904-a-904-c and / or periodically communicated to the simulator 902. The simulator 902 is configured to perform, for example, data mining, including normalization, thus enabling a simulation-based analysis of the physiological effects of the human 906 on the drug-simulating signals. To that end, the simulator 902 includes a data mining component 908, which implements a process for extracting and discovering patterns in a data set. The data mining component 908 has a general goal of extracting data from the data set and transforming the extracted data into information with an understandable structure for future use. Data mining may also include database and data management, data pre-processing, model and inference considerations, metric processing, complexity considerations, post-processing of discovered structures, visualization, etc.

[0079] The data mining component 908 standardizes the data, allowing it to have a common format or use a common taxonomy. Additionally, the sensor data can be classified with respect to certain performance metrics. For example, the data mining component 908 can extract temperature measurements and classify the sensor data with respect to the location of the sensors 904-a-904-c that captured the temperature measurements, with respect to characteristics or demographics of the human 906, and / or with respect to other dimensions that can be used to classify this data. In another implementation, the data mining component 908 performs data aggregation to compile data extracted and combined from the datasets to prepare new datasets for optimization of processing by other components of the simulator 902.

[0080] The simulator 902 includes a modeling component 910, such as an ML modeling algorithm. The modeling component 910 builds computer algorithms that improve automatically with experience and additional data. For example, the ML algorithm may build a model or training data set based on sample sensor data to allow predictions or forecasts or decisions to be made regarding the effectiveness of the drug-simulating signal based on simulated changes. In another implementation, the modeling component 910 includes a catalog function that is manually generated and updated based on the sensor data. This allows predictions of the effects of the drug-simulating signal on the target physiological system when comparing data against the sensor data catalog and performing interpolation or other numerical, computational, or statistical methods to estimate how certain changes will affect the performance of the drug-simulating signal.

[0081] The simulator 902 includes a simulation component 912 that is configured to induce states of one or more physiological systems in response to changes in any of those systems or changes in any of the drug-mimicking signals. For example, the simulation component 912 can simulate the effects of the same drug-mimicking signal on people of different weights or ages. These simulations require the use of models generated by the model component 910, which represent important properties or behaviors of the physiological system or process of interest. The simulations, in turn, represent the evolution of the models over time or in response to changes.

[0082] The simulator 902 includes an analytics component 914 that may generate and / or manage a network portal. One example includes an online web-based portal. The portal may display the simulation or related data through visualizations or other user-friendly features. The user-friendly features allow an end user 916 to explore the simulation and learn procedures to improve the effectiveness of the drug mimicking signal. The analytics component 914 allows for continuous iterative exploration and exploration of past performance to predict future performance in various scenarios. The analytics component 914 utilizes statistical techniques to provide a data-driven understanding of the physiological system of interest and related systems and develop new insights regarding the performance of multiple physiological systems. The analytics component 914 facilitates decision making through extensive use of tools, analytical modeling, including explanatory and predictive modeling, and numerical analysis, as well as fact-based management.

[0083] End user 916 includes any end user device operable by a user or computing device that has authorization to access the components or data processed by simulator 902. In one example, end user 916 is assigned a role that allows access to one, any, or all of the components of simulator 902. For example, an end user with a reviewer role is only allowed access to the analysis component 914, while an end user with an administrator role is allowed access to all components of simulator 902, such as to edit models in modeling component 910 and change the way data sets are aggregated by data mining component 908.

[0084] In a test scenario, various drug-mimicking signals are prototyped in an environment where each organism is exposed to various types of drug-mimicking signals or to various combinations of types and to various intensities, thereby determining the effectiveness of the signals to achieve the desired physiological effect. A camera can be positioned to monitor each organism and provide feedback on their state under specific conditions. In that way, the system 900 can be optimized to determine the drug-mimicking signal with the highest efficacy. The system 900 can be equipped with multiple sensors 904-a to 904-c (e.g., 8 sensors) required for 3D environmental measurements to simulate 3D modulation of the surface potential of molecules. In that way, the system 900 can automate the discovery of the most efficacious signal and realize improved post-processing to automate batch processing of signals. In the case of testing, for example, the system 900 can process multiple signals in a batch process to make a determination as to which signal between the bands below 6 kHz caused the most efficacious physiological effect.

[0085] 10 is a block diagram illustrating an example of a computer system 1000 that may implement at least some operations described herein. As shown, the computer system 1000 may include one or more processors 1002, a main memory 1006, a non-volatile memory 1010, a network interface device 1012, a video display device 1018, an input / output device 1020, a control device 1022 (e.g., a keyboard and a pointing device), a drive unit 1024 with a storage medium 1026, and a signal generating device 1030, which are communicatively coupled to a bus 1016. The bus 1016 represents one or more physical buses and / or point-to-point connections connected by appropriate bridges, adapters, or controllers. Additionally, the computer system 1000 may include common components such as a cache memory (not shown). Additionally, computer system 1000 is intended to represent a hardware device in which the components shown or described in connection with the drawing examples, as well as any other components described herein, may be implemented.

[0086] The computing system 1000 may take any suitable physical form. For example, the computing system 1000 may share a similar architecture as a server computer, a personal computer (PC), a tablet computer, a mobile phone, a game console, a music player, a wearable electronic device, a network-connected ("smart") device (e.g., a television or a home assistant device), an AR / VR system (e.g., a head-mounted display), or any electronic device capable of executing a set of instructions that specify actions to be performed by the computing system 1000. In some implementations, the computing system 1000 may be an embedded computing system, a system-on-chip (SOC), a single-board computer system (SBC), or a distributed system, such as a mesh of computing systems, or may comprise one or more cloud components in one or more networks. Where appropriate, one or more of the computing systems 1000 may perform operations in real-time, near real-time, or batch mode.

[0087] The network interface device(s) 1012 enable the computing system 1000 to broker data within the network 1014 between the computing system 1000 and entities external to the computing system 1000 via any communication protocol supported by the computing system 1000 and the external entities. Examples of the network interface device(s) 1012 include network adapter cards, wireless network interface cards, routers, access points, wireless routers, switches, multi-layer switches, protocol converters, gateways, bridges, bridge routers, hubs, digital media receivers, and / or repeaters, as well as any wireless elements referred to herein.

[0088] The memory (e.g., main memory 1006, non-volatile memory 1010, machine-readable medium 1026) can be local, remote, or distributed. Although the machine-readable medium 1026 is illustrated as a single medium, it can comprise multiple media (e.g., centralized / distributed databases and / or associated caches and servers) that store one or more sets of instructions 1028. The machine-readable (storage) medium 1026 can comprise any medium capable of storing, encoding, or carrying a set of instructions to be executed by the computing system 1000. The machine-readable medium 1026 can be non-transitory or can comprise a non-transitory device. In this context, a non-transitory storage medium can comprise a device that is tangible, meaning that the device has a concrete physical form, but that its physical state can change. For example, the term non-transitory means that the device remains tangible even when this state change occurs.

[0089] Although implementations have been described in the context of a fully functional computing device, various examples may be distributed as a program product in a variety of forms. Examples of machine-readable storage media, machine-readable media, or computer-readable media include (1) recordable media, such as volatile and non-volatile memory devices 1010, (2) removable flash memory, (3) hard disk drives, (4) optical disks, and (5) transmission-type media, such as digital and analog communications links.

[0090] Generally, the routines executed to implement the examples herein may be implemented as part of an operating system or a specific application, component, program, object, module, or sequence of instructions (collectively referred to as a "computer program"). Typically, these computer programs comprise one or more instructions (e.g., instructions 1004, 1008, 1028) that are configured at various times in various memory and storage devices within a computing device. These instructions, when read and executed by processor 1002, cause computing system 1000 to perform operations to implement elements associated with various aspects of the present disclosure.

[0091] definition The following terms generally have the following definitions unless otherwise indicated. Although such definitions are brief, they will assist those skilled in the relevant art to more fully understand the aspects of the present invention based on the detailed description provided herein. For other definitions, see above. Such definitions are further defined by the entirety of the description of the present invention (including the claims) and not by these definitions alone.

[0092] "Radio frequency energy" refers to a magnetic field having a frequency in the range of approximately 0 Hz to 22 kHz.

[0093] "Magnetic shield" refers to a shield that reduces, inhibits, or prevents the passage of magnetic flux as a result of the magnetic permeability of the shield material.

[0094] "Electromagnetic shield" refers to a standard Faraday electromagnetic shield or other method for reducing the passage of electromagnetic radiation.

[0095] "Faraday cage" refers to an electromagnetic shielding configuration that provides an electrical path to ground for unwanted electromagnetic radiation, thereby quieting the electromagnetic environment.

[0096] A "time domain signal" or "time series signal" refers to a signal that has transient signal characteristics that change over time.

[0097] "Sample source radiation" refers to magnetic or electromagnetic flux emission resulting from molecular motion of a sample, such as the rotation of molecular dipoles in a magnetic field. Because sample source radiation can be generated in the presence of an injected magnetic field stimulus, it may also be referred to as "sample source radiation superimposed on an injected magnetic field stimulus."

[0098] "Stimulating magnetic field" or "magnetic field stimulus" refers to a magnetic field produced by injecting (applying) one of the following electromagnetic signals to a magnetic coil surrounding a sample, which may include (i) white noise injected at a voltage level calculated to produce a selected magnetic field at the sample between 0 and 1 Gauss (G), (ii) a DC offset injected at a voltage level calculated to produce a selected magnetic field at the sample between 0 and 1 G, and / or (iii) a sweep over a low frequency range injected continuously over a sweep range between at least 0 and 1 kHz and with an injection voltage calculated to produce a selected magnetic field at the sample between 0 and 1 G. The magnetic field produced at the sample may be readily calculated using known electromagnetic relationships, given the geometry and number of turns of the injection coil, the voltage applied to the coil, and the distance between the injection coil and the sample.

[0099] "Selected stimulation magnetic field condition" indicates the selected applied voltage relative to a white noise or DC offset signal, or the selected sweep range, sweep frequency, and voltage of the applied swept stimulation magnetic field.

[0100] "White noise" refers to random noise or a signal that has multiple frequencies simultaneously (e.g., white random noise or deterministic noise). Multiple variations of white noise and other noise may be used. For example, "Gaussian white noise" is white noise that has a Gaussian power distribution.

[0101] "Stationary Gaussian white noise" is random Gaussian white noise that has no predictable future component.

[0102] "Structured noise" is white noise that may contain logarithmic characteristics that shift the energy from one region of the spectrum to another, or may be designed to provide a random time element in which the amplitude remains constant. These two have pink uniform noise when compared to true random noise, which has no predictable future component whatsoever.

[0103] "Uniform noise" refers to white noise that has a rectangular distribution rather than a Gaussian distribution.

[0104] A "frequency domain spectrum" refers to a Fourier frequency plot of a time domain signal.

[0105] A "spectral component" refers to a single or repeating feature in a time domain signal that is measurable in the frequency, amplitude, and / or phase domain. Typically, a spectral component refers to a signal that exists in the frequency domain.

[0106] "Examples" 1. A method for generating a drug mimetic signal for simulating a physiological effect of a drug on a living organism, comprising: measuring an electrostatic potential associated with a physiological system of the living body under the influence of a drug; recording the measured electrostatic potential of the physiological system in a memory of the closed system; generating a drug-mimicking signal based on recorded measurements of electrostatic potential of a physiological system; The drug-simulating signal is controlled using a closed system amplifier circuit. the drug-mimicking signal comprises an electromagnetic signal configured to simulate an effect of a drug on a living organism; while irradiated with the drug-mimicking signal, causing a closed system amplifier circuit to manipulate the drug-mimicking signal based on feedback including a measurement of an electrostatic potential associated with the physiological system to produce a desired physiological effect; controlling delivery of a drug-mimicking signal within the closed system in response to the feedback and based on a computer program stored in a memory within the closed system; dynamically adapting the efficacy of the drug mimicking signal to a desired physiological effect in response to feedback collected by the closed system. A method comprising: 2. The method of Example 1, wherein the closed system comprises a wearable device, a handheld device, or a combination of the wearable device and the handheld device. 3. The method of Example 1, wherein the drug-simulating signal is enhanced by filtering and / or truncating a portion of the drug-simulating signal, which portion produces a physiological effect. 4. The method of any one of Examples 1 to 3, wherein the drug-mimicking signal producing a physiological effect is filtered through a 6 kHz filter and / or a 7 kHz filter. 5. A method according to any one of Examples 1 to 3, wherein the drug-mimicking signal producing a physiological effect is (1) downsampled from about 44.1 kHz to below 11 kHz, and (2) upsampled to 44.1 kHz. 6. The method of any one of Examples 1 to 5, wherein low-pass filtering and down-sampling produce a physiological effect by removing unwanted radio frequency (RF) energy radiated to the living body during delivery of a drug-mimicking signal. 7. The method of Example 6, wherein unwanted RF energy competes with frequencies responsible for the physiological effect. 8. Low-pass filtering and down-sampling to reduce the file size of the drug-simulated signal, as described in Example 6. 9. A method for optimizing a drug-mimicking signal based on data obtained after delivery of the drug-mimicking signal to a living body, comprising: Detecting the effectiveness of the drug mimicking signal delivered to the living body by: generating one or more drug mimicking signals for delivery to a living organism; and Measuring the physiological effects of the delivered drug-mimicking signal on the living body using a sensor detecting the signal by Improving the effectiveness of the delivered drug mimicking signal to the organism with a machine learning model, the machine learning model comprising: creating a training data set from the physiological effect data collected by the sensor; enabling the drug mimicking signal to make a prediction or decision based on a training data set; and Dynamic Adaptation to Improve the Effectiveness of Drug Mimicking Signals and A method comprising: 10. The method of Example 9, wherein the step of improving the effectiveness of a drug-mimicking signal delivered to produce a physiological effect in a living organism is performed by a system including a simulator configured to process records of electrostatic potentials of drugs and / or other substances collected by a sensor. 11. The method of Example 10, wherein the drug-mimicking signal corresponds to an electromagnetic signal that produces a physiological effect. 12. The electrostatic potential is chemical molecules, biochemical molecules, and biological molecules The method of Example 11, wherein the molecule is generated from a molecule selected from the group consisting of: 13. The method of Example 9, wherein the step of generating one or more drug-mimicking signals for delivery to a living body is performed by a signal generator. 14. The method of any one of Examples 9 to 10, wherein the sensor measures a physical property of the living body caused by the physiological effect of the delivered drug-mimicking signal. 15. The method of Example 14, wherein the physical properties of the living body include properties indicative of a physiological effect of the drug-mimicking signal. 16. The method of Example 15, wherein the characteristic indicative of the physiological effect of the drug-mimicking signal is the temperature of the living body. 17. The method of example 10, wherein the communication channel communicates a drug-simulating signal between the living body and the simulator. 18. The sensor is Magnetometer, Proximity sensors, Barometer, Gyroscope, and accelerometer 15. The method of any one of Examples 9, 10, or 14, comprising one or more sensors selected from the group consisting of: 19. The method of Example 9, wherein the step of creating a training dataset from physiological effect data collected by the sensor to improve the effectiveness of the drug-simulating signal is performed by a modeling component. 20. The method of example 19, wherein the modeling component includes a predictive determination regarding the effectiveness of the drug-mimicking signal. 21. The method of example 20, wherein the prediction determination is based on simulated changes by a simulation component. 22. The method of example 10, wherein the simulator further comprises an analysis component that manages the network portal. 23. The method of example 22, wherein the analysis component includes continually iteratively exploring and examining past performance to predict future performance during various events. 24. A device configured to deliver a drug-mimicking signal that, when emitted to a living organism, produces a physiological effect in the living organism, comprising: a plurality of integrated circuit chips; Multiple sensors, a communications circuit configured to support a wireless communications protocol; or Any combination of integrated circuit chips, sensors, and communication circuits A device comprising: 25. Multiple sensors are Magnetometer, Proximity sensors, Barometer, Gyroscope, and accelerometer The device of Example 24, comprising one or more sensors selected from the group consisting of: 26. The device of Example 24, wherein the device is configured to achieve a physiological effect in a living organism by selecting an appropriate drug-mimicking signal via a supported wireless communication protocol. 27. The device of Example 26, wherein the communication protocol comprises Bluetooth, Wi-Fi, satellite navigation, or any combination of Bluetooth, Wi-Fi, and satellite navigation. 28. The device of example 24, wherein the device is a wearable device. 29. The device is Smart Watch, Smart eyewear, and Wearables Display Devices The device of Example 28, comprising one or more devices selected from the group consisting of: 30. A controller for distributing and adjusting a drug-simulating signal to a signal generator, comprising: housing, Processor, Memory, A visual and audio interface, or Any combination of housing, processor, memory, and visual and audio interfaces A controller comprising: 31. The controller of Example 30, wherein the controller further comprises a microcontroller circuit and a signal generating circuit. 32. The controller of example 31, wherein the microcontroller circuit is configured to operate the controller. 33. A microcontroller circuit is Microprocessor, A reset circuit, and Volatile Memory The controller of Example 31, comprising: 34. The controller of example 33, wherein the microprocessor has a plurality of analog and / or digital communication pins for communicating inside and outside the housing. 35. A microprocessor is: USB connector, A display connector for the visual interface, and Audio Connectors for Audio Interfaces The controller of Example 34, further comprising: 36. The controller of example 31, wherein the signal generating circuit is configured to drive the coil and cable assembly with a drug-simulating signal. 37. A signal generating circuit is Audio Coder-Decoder, an output amplifier; and Current Monitor The controller of Example 36, comprising: 38. The controller of Example 37, wherein the audio coder-decoder is configured to output an analog output drug-simulating signal to the output amplifier. 39. The controller of example 37, wherein the output amplifier comprises a low pass filter. 40. The controller of example 37, wherein the output amplifier is programmable. 41. The controller of Example 37, wherein the output amplifier is further configured to adjust the intensity level of the input drug-simulating signal received by the coil of the coil and cable assembly. 42. The controller of Example 37, wherein a current monitor determines electrical characteristics of the coil and cable assembly. 43. The controller of Example 37, wherein the current monitor verifies that the drug-simulating signal level remains within a specified frequency threshold. 44. A method for manufacturing a coil and cable assembly for use during non-invasive delivery of a drug-mimetic signal to simulate a physiological effect in a living organism, comprising: encapsulating the coil within a flexible composite material; coupling a connector to the coil; coupling an integrated circuit to the coil, the connector, and the cable; incorporating memory storage into the integrated circuit; A method comprising: 45. The method of example 44, wherein the step of coupling the integrated circuit to the cable further includes the step of providing mechanical strain relief for a plurality of conductors for delivering signals between the connector and the coil. 46. ​​The method of example 44, wherein the memory storage is configured to identify electrical characteristics of the integrated circuit, connector, cable, and / or coil. 47. The method of example 44, wherein the coil and cable assembly is configured to be encapsulated within the wearable device.

[0107] conclusion The systems described herein can be configured to transduce certain molecular signals to effect certain charge pathways, delivering the effects of chemical, biochemical, or biological therapy to patients to treat deteriorated health conditions without drugs, replacement therapies, etc. For example, the systems can transduce RNA sequence signals to regulate metabolic pathways and protein production, both up- and down-regulation.

[0108] This system offers many other advantages: The system is scalable to provide treatment to various areas of the patient; The coils, cables and connectors are disposable, or the entire device including the controller is preferably provided for a limited treatment session and one prescription, thus preventing reuse of the device and coils, thus preventing cross contamination, etc. A switch on the device provides on / off treatment, allowing the patient to selectively turn their treatment on / off as needed.

[0109] Unless the context clearly requires otherwise, throughout this description and claims, words such as "comprises" and "comprising" should be interpreted in a non-exclusive, rather than exclusive or inclusive, sense, i.e., "comprises but is not limited to." The term "coupled" as generally used herein indicates that two or more elements may be connected either directly or through one or more intermediate elements. Furthermore, when used in this application, the words "herein," "above," "below," and words of similar import refer to this application as a whole and not to any particular portion of this application. Where the context permits, words using the singular or plural in the above detailed description may further include the plural or singular, respectively. The word "or" in reference to a list of two or more items includes all of the following interpretations of that word, namely, any of the items in the list, all of the items in the list, and any combination of the items in the list.

[0110] The above detailed description of embodiments of the invention is not intended to be exhaustive or to limit the invention to the precise form disclosed above. Although specific embodiments and examples of the invention are described above for illustrative purposes, those skilled in the relevant art will recognize that various equivalent modifications are possible within the scope of the invention. For example, although processes or blocks are presented in a certain order, alternative embodiments may perform routines having steps in a different order or use systems having blocks in a different order, and some processes or blocks may be deleted, moved, added, sub-divided, combined, and / or modified. Each of these processes or blocks may be implemented in a variety of different ways. Also, while processes or blocks are sometimes shown as being performed sequentially, these processes or blocks may instead be performed in parallel or at different times.

[0111] The teachings of the invention presented herein are not necessarily limited to the systems described above and may be applied to other systems as well. Elements and operations of the various embodiments described above may be combined to realize further embodiments.

[0112] All of the above patents and applications and other references, including any that may be listed in accompanying application papers, are incorporated herein by reference. Aspects of the invention can be modified, as necessary, to employ the systems, functions, and concepts of the various references described above to achieve still other embodiments of the invention.

[0113] These and other changes can be made to the invention in light of the above detailed description. The above description details certain embodiments of the invention and describes the best mode contemplated, but no matter how detailed the above description is presented in text, the invention can be practiced in many ways. The details of the signal processing system may vary widely in their implementation details, yet remain encompassed by the invention disclosed herein.

[0114] As stated above, a particular term used when describing a particular feature or aspect of the present invention should not be interpreted as meaning that the term is redefined herein to be limited to the particular characteristic, feature, or aspect of the present invention associated with the term. In general, unless expressly defined in the Detailed Description section above, the terms used in the appended claims should not be interpreted as limiting the present invention to the particular embodiments disclosed herein. Thus, the actual scope of the present invention encompasses not only the disclosed embodiments, but also any equivalent ways of practicing or implementing the present invention under the scope of the claims.

Claims

1. 1. A method for generating a drug-mimetic signal for simulating a physiological effect of a drug on a living organism, comprising: measuring an electrostatic potential associated with a physiological system of the living body under the influence of the drug; recording the measurement of the electrostatic potential of the physiological system in a memory of a closed system; generating the drug-simulating signal configured based on the recording of the measurements of the electrostatic potential of the physiological system, the drug-simulating signal is controlled using the closed system amplifier circuit; the drug-mimicking signal comprises an electromagnetic signal configured to simulate an effect of the drug on the living organism; causing the amplifier circuit of the closed system to manipulate the drug-mimicking signal based on feedback including a measurement of an electrostatic potential associated with the physiological system to produce a desired physiological effect while irradiated with the drug-mimicking signal; controlling delivery of the drug-simulating signal within the closed system in response to the feedback and based on a computer program stored in the memory within the closed system; dynamically adapting the efficacy of the drug-mimicking signal to the desired physiological effect in response to feedback collected by the closed system; A method comprising:

2. The method of claim 1 , wherein the closed system comprises a wearable device, a handheld device, or a combination of the wearable device and the handheld device.

3. 10. The method of claim 1, wherein the drug-simulating signal is enhanced by filtering and / or truncating a portion of the drug-simulating signal, the portion causing the physiological effect.

4. 10. The method of claim 1, wherein the drug-mimicking signal producing the physiological effect is filtered through a 6 kHz filter and / or a 7 kHz filter.

5. 2. The method of claim 1, wherein the drug-mimicking signal producing the physiological effect is (1) downsampled from about 44.1 kHz to below 11 kHz, and (2) upsampled to 44.1 kHz.

6. 6. The method of claim 1, wherein low-pass filtering and down-sampling remove unwanted radio frequency (RF) energy radiated to the living body during delivery of the drug-simulating signal, thereby producing the physiological effect.

7. 7. The method of claim 6, wherein the unwanted RF energy competes with frequencies responsible for the physiological effect.

8. The method of claim 6 , wherein the low-pass filtering and the down-sampling reduce the file size of the drug-simulating signal.

9. 1. A method for optimizing a drug-mimicking signal based on data obtained after delivery of the drug-mimicking signal to a living organism, comprising: detecting the effectiveness of the drug-mimicking signal delivered to the living body, generating one or more drug-mimicking signals for delivery to the organism; and measuring a physiological effect of the delivered drug-mimicking signal on the living body with a sensor; detecting by Improving the effectiveness of the delivered drug-mimicking signal on the organism with a machine learning model, the machine learning model comprising: creating a training dataset from the physiological effect data collected by the sensors; enabling the drug-simulating signal to make predictions or decisions based on the training dataset; and Dynamically adapting the drug-mimicking signal to improve the effectiveness. and steps to improve A method comprising:

10. 10. The method of claim 9, wherein the step of improving the effectiveness of the delivered drug-mimicking signal to produce the physiological effect in the living organism is performed by a system comprising a simulator configured to process recordings of electrostatic potentials of drugs and / or other substances collected by the sensor.

11. The method of claim 10 , wherein the drug-mimicking signal corresponds to an electromagnetic signal that produces the physiological effect.

12. The electrostatic potential is chemical molecules, biochemical molecules, and biological molecules The method of claim 11 , wherein the molecule is generated from a molecule selected from the group consisting of:

13. 10. The method of claim 9, wherein the step of generating one or more drug-mimicking signals for delivery to the living body is performed by a signal generator.

14. 11. The method of claim 9 or 10, wherein the sensor measures a physical property of the living body caused by the delivered drug-mimicking signal under the physiological effect.

15. The method of claim 14 , wherein the physical property of the living body comprises a property indicative of the physiological effect of the drug-mimicking signal.

16. The method of claim 15 , wherein the characteristic indicative of the physiological effect of the drug-mimicking signal is the temperature of the living body.

17. The method of claim 10 , wherein a communication channel communicates the drug-simulating signal between the living body and the simulator.

18. The sensor magnetometer, Proximity sensors, barometer, gyroscope, and accelerometer 11. The method of claim 9 or 10, comprising one or more sensors selected from the group consisting of:

19. 10. The method of claim 9, wherein the step of creating the training data set from the physiological effect data collected by the sensor to improve the effectiveness of the drug-simulating signal is performed by a modeling component.

20. 20. The method of claim 19, wherein the modeling component comprises a predictive determination regarding the effectiveness of the drug-simulating signal.

21. The method of claim 20 , wherein the prediction determination is based on simulated changes by a simulation component.

22. The method of claim 10 , wherein the simulator further comprises an analysis component that manages network portals.

23. 23. The method of claim 22, wherein the analysis component includes continually iteratively exploring and examining past performance to predict future performance during various events.

24. 1. A device configured to deliver a drug-mimicking signal that, when emitted to a living organism, produces a physiological effect in the organism, comprising: a plurality of integrated circuit chips; Multiple sensors, communications circuitry configured to support a wireless communications protocol; or Any combination of the plurality of integrated circuit chips, the plurality of sensors, and the communication circuitry. A device comprising:

25. The plurality of sensors include: magnetometer, Proximity sensors, barometer, gyroscope, and accelerometer 25. The device of claim 24, comprising one or more sensors selected from the group consisting of:

26. 25. The device of claim 24, wherein the device is configured to achieve the physiological effect in the living organism by selecting an appropriate drug-mimicking signal over a supported wireless communication protocol.

27. 27. The device of claim 26, wherein the supported wireless communication protocols comprise Bluetooth, Wi-Fi, satellite navigation, or any combination of the Bluetooth, the Wi-Fi, and the satellite navigation.

28. 25. The device of claim 24, wherein the device is a wearable device.

29. The device comprises: Smart watches, Smart eyewear, and Wearables Display Devices 30. The device of claim 28, comprising one or more devices selected from the group consisting of:

30. a controller for distributing and coordinating a drug-simulating signal to the signal generator, housing, processor, memory, Visual and audio interfaces, or Any combination of the housing, the processor, the memory, and the visual and audio interface. A controller comprising:

31. 31. The controller of claim 30, wherein the controller further comprises a microcontroller circuit and a signal generation circuit.

32. 32. The controller of claim 31, wherein the microcontroller circuit is configured to operate the controller.

33. The microcontroller circuit microprocessor, a reset circuit, and Volatile Memory 32. The controller of claim 31 , comprising:

34. 34. The controller of claim 33, wherein the microprocessor includes a plurality of analog and / or digital communication pins for communicating inside and outside the housing.

35. The microprocessor USB connector, a display connector for a visual interface; and Audio connector for audio interface 35. The controller of claim 34, further comprising:

36. 32. The controller of claim 31, wherein the signal generating circuit is configured to drive a coil and cable assembly with the drug-simulating signal.

37. The signal generating circuit Audio coder-decoder, an output amplifier; and Current Monitor 37. The controller of claim 36, comprising:

38. 38. The controller of claim 37, wherein the audio coder-decoder is configured to output an analog output drug-simulating signal to the output amplifier.

39. 38. The controller of claim 37, wherein the output amplifier comprises a low pass filter.

40. 38. The controller of claim 37, wherein the output amplifier is programmable.

41. 38. The controller of claim 37, wherein the output amplifier is further configured to adjust an intensity level of an input drug-simulating signal received by a coil of the coil and cable assembly.

42. 38. The controller of claim 37, wherein the current monitor determines an electrical characteristic of the coil and cable assembly.

43. 38. The controller of claim 37, wherein the current monitor verifies that the drug-simulating signal level remains within a specified frequency threshold.

44. 1. A method for manufacturing a coil and cable assembly for use during non-invasive delivery of a drug-mimicking signal to simulate a physiological effect in a living organism, comprising: encapsulating the coil within a flexible composite material; coupling a connector to the coil; coupling an integrated circuit to the coil, the connector, and the cable; incorporating memory storage into said integrated circuit; A method comprising:

45. 45. The method of claim 44, wherein the step of coupling the integrated circuit to the cable further comprises providing mechanical strain relief for a plurality of conductors for carrying signals between the connector and the coil.

46. 45. The method of claim 44, wherein the memory storage is configured to identify electrical characteristics of the integrated circuit, the connector, the cable, and / or the coil.

47. 45. The method of claim 44, wherein the coil and cable assembly is configured to be encapsulated within a wearable device.

Images